P. E. Dyakonov

P. E. Dyakonov

Auto-generated profile, based on publicly available information

P. E. Dyakonov

The Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2022 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
OHOncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
ARA.A. Roppelt
A.A. Roppelt
DYD.V. Yukhacheva
D.V. Yukhacheva
PDP.E. D’yakonov
P.E. D’yakonov
IHI.G. Hamin
I.G. Hamin
ASA.Yu. Shcherbina
A.Yu. Shcherbina
Rapid desensitization therapy (RDT) is a drug administration procedure when temporary tolerance to the medication can be reached within several hours. The method is based on the stepwise administration of increasing doses of the medication, starting from minimal dose until the total target dose is achieved. RDT is widely used when a severe allergic reaction (up to anaphylaxis) develops to a vital irreplaceable drug. The RDT procedure has proven to be effective and safe with the use of chemotherapy drugs, monoclonal antibody drugs, certain antibiotics, and enzyme replacement therapy. The article presents the first Russian case of RDT to imiglucerase in a patient with Gaucher disease and an anaphylactic reaction to imiglucerase.

14 April 2026 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
AIA. Y. Ivanashkin
A. Y. Ivanashkin
PDP. E. Dyakonov
P. E. Dyakonov
ERE. A. Ryadinskaya
E. A. Ryadinskaya
IKI. A. Kryukov
I. A. Kryukov
VLV. V. Lazarev
V. V. Lazarev
NGN. S. Grachev
N. S. Grachev
Introduction. Extracorporeal membrane oxygenation (ECMO) is increasingly used in pediatric oncology patients with severe cardiac and/or respiratory failure. However, experience with this technique in this population remains limited, particularly in Russia. Materials and methods. Here we retrospectively reviewed the first 5 cases of peripheral venoarterial ECMO use in children with malignancies (4 females, 1 male) treated at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology from October 2024 to May 2025. The median age was 12 years. Indications, patient selection criteria, ECMO duration, complications, and outcomes were analyzed. Results. In 4 out of 5 patients, ECMO was initiated due to refractory cardiac and/or respiratory failure, and in 1 case, it was used as intraoperative support. The median ECMO duration was 5 days; the median length of stay at the Intensive Care Unit was 20 days. Four patients were successfully decannulated and subsequently discharged. One patient died due to oxygenator thrombosis. Despite the extreme illness severity at baseline (pSOFA 9, VIS 95, VVR 112), no major infectious or hemorrhagic complications occurred. Conclusion. In this paper, we reported the first Russian experience of ECMO use in children with cancer demonstrating that not only is it in principle possible but also effective, as long as a multidisciplinary approach and strict selection criteria are adopted and a trained team of specialists are on hand.